Molecular Diagnostics in Urologic Malignancies.
Context.-Molecular diagnostic applications are now an integral part of the management algorithms of several solid tumors, such as breast, colon, and lung. In stark contrast, the current clinical management of urologic malignancies is lagging behind. Clinically robust molecular tests that can identif...
| Publicado en: | Archives of Pathology & Laboratory Medicine Vol. 135; no. 5; pp. 610 - 622 |
|---|---|
| Autor principal: | |
| Formato: | pictorial review tables/charts Journal Article |
| Publicado: |
College of American Pathologists
May2011
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=60805864&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 60805864 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 00039985 1FS jtl: Archives of Pathology & Laboratory Medicine issn: 00039985 maglogo: N pubinfo: dt: May2011 vid: 135 iid: 5 pid: 2550 pub: College of American Pathologists place: Northfield, Illinois artinfo: ui: 60805864 60805864 104708482 10.5858/2010-0727-rair.1 60805864 ppf: 610 ppct: 12 formats: fmt: @attributes: type: P tig: atl: Molecular Diagnostics in Urologic Malignancies. aug: au: Netto, George J. affil: Departments of Pathology, Urology, and Oncology, Johns Hopkins Medical Institutions, Baltimore, Maryland sug: subj: Urologic Neoplasms Diagnosis Molecular Diagnostic Techniques Mutation Urologic Neoplasms Familial and Genetic Urologic Neoplasms Pathology Tumor Markers, Biological Prognosis Genomics Urologic Neoplasms Physiopathology Carcinoma, Renal Cell Diagnosis Carcinoma, Renal Cell Pathology In Situ Hybridization, Fluorescence ab: Context.-Molecular diagnostic applications are now an integral part of the management algorithms of several solid tumors, such as breast, colon, and lung. In stark contrast, the current clinical management of urologic malignancies is lagging behind. Clinically robust molecular tests that can identify patients who are more likely to respond to a given targeted agent or even those in need of a more aggressive treatment based on well-validated molecular prognosticators are still lacking. Several promising biomarkers for detection, prognosis, and targeted therapeutics are being evaluated. Objective.-To discuss candidate biomarkers that may soon make the transition to clinical assay for patients in urologic oncology. Data Sources.-Selected original articles published in the PubMed service of the US National Library of Medicine. Conclusions.-Recent understanding of the complex molecular alterations involved in the development and progression of urologic malignancies is yielding novel diagnostic and prognostic molecular tools and opening the doors for experimental targeted therapies in these prevalent, frequently lethal solid tumors. pubtype: Academic Journal doctype: pictorial review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|